From here.
Pfizer Inc. said Friday that a European Union advisory panel recommended that its lung cancer drug Xalkori get conditional marketing approval.
The panel recommended that Xalkori be approved conditionally for use in patients who have already received at least one treatment for lung cancer. The non-binding opinion will be considered by EU regulators. Pfizer said that if Xalkori gets conditional approval, it will be required to submit data from a recently completed clinical trial. Regulators could give the drug full approval after reviewing those results.
Drugs that address unmet medical needs sometimes get conditional approvals so patients can use the products before they get full marketing approval. Xalkori targets cancer linked to a genetic mutation found in less than 7 percent of non-small cell lung cancer patients.
Well, it is really lucky news for those 7% who has these special mutation. The doctors are probably inform patients in a following way: "I have two news for you: one bad and one good. The bad news is that you have non-small lung cancer, and the good one is that the cancer has a special mutation..."
No comments:
Post a Comment